The treatment suppresses uterine sensitization-associated gene-1 protein, which typically prevents the regrowth of teeth.
The trial will include 30 men between the ages of 30 and 64 who are missing at least one molar. The study could also be expanded to include individuals who are missing up to five permanent teeth and children between 2 and 7 years old who are missing at least four teeth.
Scientists at Kyoto University Hospital in Japan will conduct the study from September 2024 to August 2025. The drug was previously tested on ferrets and mice and caused no notable side effects.
If the trial is successful, the drug could become commercially available in 2030, the report said.
The clinical trial was first announced in July 2023.
At the Becker's 5th Annual Future of Dentistry Roundtable, taking place September 14-15 in Chicago, dental leaders and executives will gain insights into emerging technologies, practice growth strategies and the evolving landscape of dental care delivery, with a focus on innovation, patient experience and operational excellence. Apply for complimentary registration now.
